The research of Naveen L. Pereira, M.D., involves performing resequencing studies to describe common genetic variations in cardiovascular disease. He aims to determine the functional significance of these genetic variations by using basic molecular techniques in his National Institutes of Health (NIH)-funded population studies.
- Elucidate the association of genetic variants with biomarkers, adverse drug responses and disease states
- Evaluate the utility and applicability of genetic variants that could modulate drug response in clinical practice
- Perform genotype-based, international, multicenter, randomized, cardiovascular clinical trials
- Adopt techniques in artificial intelligence (AI) to help develop heart failure risk prediction models
- Use electronic health record data and screening for dilated cardiomyopathy using AI-enhanced electrocardiography tools
- Use disruptive digital platforms to assess, follow and transition patients enrolled in clinical trials
Significance to patient care
Dr. Pereira's research to better understand, diagnose, treat and manage cardiovascular disease contributes to improved survival and quality of life for patients.
- Clinical Trials Review Committee, National Heart, Lung, and Blood Institute, 2021-2024
- Mid-Career Award, American Heart Association (AHA), 2021
- Best poster presentation, European Society of Cardiology, 2020
- Top Poster Ribbon and Presidential Trainee Award, American Society for Clinical Pharmacology and Therapeutics, 2020
- Editorial board, Mayo Clinic Proceedings, 2019-present
- Chair, Professional/Public Education & Publications Committee, Council on Genomics and Precision Medicine, AHA, 2019